Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samira Bahl

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Genetics|May 7, 2009
Utilizing linkage disequilibrium information from Indian Genome Variation Database for mapping mutations: SCA12 case studySamira Bahl, Ikhlak Ahmed, , et al.
Molecular Autism|March 22, 2013
Lack of association of rare functional variants in TSC1/TSC2 genes with autism spectrum disorderSamira Bahl, Colby Chiang, Roberta L Beauchamp, et al.
The Journal of Biological Chemistry|July 17, 2012
The E3 ubiquitin ligase protein associated with Myc (Pam) regulates mammalian/mechanistic target of rapamycin complex 1 (mTORC1) signaling in vivo through N- and C-terminal domainsSangyeul Han, Sun Kim, Samira Bahl, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
Cell Reports|May 7, 2016
Genomic Correlates of Immune-Cell Infiltrates in Colorectal CarcinomaMarios Giannakis, Xinmeng Jasmine Mu, Sachet A Shukla, et al.
Cancer Discovery|May 19, 2017
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function <i>ERF</i> MutationsFranklin W Huang, Juan Miguel Mosquera, Andrea Garofalo, et al.
Cancer Discovery|August 7, 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinomaEliezer M Van Allen, Kent W Mouw, Philip Kim, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Genetics|May 7, 2009
Utilizing linkage disequilibrium information from Indian Genome Variation Database for mapping mutations: SCA12 case studySamira Bahl, Ikhlak Ahmed, , et al.
Molecular Autism|March 22, 2013
Lack of association of rare functional variants in TSC1/TSC2 genes with autism spectrum disorderSamira Bahl, Colby Chiang, Roberta L Beauchamp, et al.
The Journal of Biological Chemistry|July 17, 2012
The E3 ubiquitin ligase protein associated with Myc (Pam) regulates mammalian/mechanistic target of rapamycin complex 1 (mTORC1) signaling in vivo through N- and C-terminal domainsSangyeul Han, Sun Kim, Samira Bahl, et al.
Cancer Discovery|February 13, 2015
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway AlterationsLeanne G Ahronian, Erin M Sennott, Eliezer M Van Allen, et al.
Cell Reports|May 7, 2016
Genomic Correlates of Immune-Cell Infiltrates in Colorectal CarcinomaMarios Giannakis, Xinmeng Jasmine Mu, Sachet A Shukla, et al.
Cancer Discovery|May 19, 2017
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function <i>ERF</i> MutationsFranklin W Huang, Juan Miguel Mosquera, Andrea Garofalo, et al.
Cancer Discovery|August 7, 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinomaEliezer M Van Allen, Kent W Mouw, Philip Kim, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Pageof 1